Dear epgnyc, Both of these regimens as an adjuvant treatment in breast cancer are acceptable. An anthracycline containing regimen (
adriamycin, the A in AC) shows a small but statistically significant improvement in survival compared to nonanthracycline-containing regimens (such as CMF). However, there is a risk of
cardiacCardiac catheterization
Cardiac tamponade
Left heart ventricular angiography toxicity with cumulative doses of anthracylines, although, there is no evidence of excessive cardiac toxicity in women without significant pre-existing heart disease with anthracyclines at the cumulative doses used in standard treatment regimens.
So decisions on what adjuvant regimen is used need to take into consideration the potential survival benefits versus specific concern about additional toxicity for the individual. In your case particularly because of your pre-existing heart condition the decision regarding adjuvant treatment might lean toward the non-anthracycline containing regimen.